**1. NCT07062263 – Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in HER2 Positive Advanced Biliary Tract Cancer**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic/extrahepatic cholangiocarcinoma or gallbladder cancer).**
* **HER2 positive status per local laboratory.**
* **At least one measurable lesion (RECIST v1.1).**
* **Life expectancy ≥12 weeks.**
* **ECOG performance status 0–1.**

**Exclusion Criteria:**

* **Prior systemic therapy for advanced/unresectable disease (adjuvant therapy allowed if completed >6 months before).**
* **CNS metastases.**
* **Significant cardiovascular disease.**
* **Active uncontrolled infections.**
* **Pregnant or breastfeeding.**

**2. NCT07052006 – HT-6184 in Subjects With MDS**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Diagnosis of Myelodysplastic Syndrome (MDS) or non-proliferative chronic myelomonocytic leukemia.**
* **Symptomatic anemia.**
* **Adequate organ function.**
* **Informed consent provided.**

**Exclusion Criteria:**

* **Other malignancy within 2 years (exceptions apply).**
* **Inadequate recovery from prior therapies.**
* **Significant comorbid illness interfering with study participation.**

**3. NCT07044687 – Venetoclax + Azacitidine in AML (Ineligible for Standard Induction)**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Confirmed diagnosis of acute myeloid leukemia (AML), untreated.**
* **Not eligible for standard induction chemotherapy.**
* **ECOG 0–3.**

**Exclusion Criteria:**

* **Prior AML treatment.**
* **Active uncontrolled infection.**
* **Other medical conditions that may interfere with participation.**

**4. NCT07042100 – Safety and Tolerability of SBO-154 in Advanced Solid Tumors**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Advanced/metastatic solid tumors that are unresectable and refractory to standard therapy.**
* **ECOG 0–1.**
* **Adequate organ function.**

**Exclusion Criteria:**

* **Major surgery within 4 weeks before first dose.**
* **Significant organ dysfunction.**
* **Any condition deemed unsuitable by investigator.**

**5. NCT07040059 – AUR103 in HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Histologically confirmed HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.**
* **ECOG 0–1.**
* **At least one measurable lesion.**

**Exclusion Criteria:**

* **Resectable tumor.**
* **Prior definitive radiotherapy to target lesions.**
* **Severe uncontrolled illness.**

**6. NCT07030517 – Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma**

**Ages Eligible for Study: 18 Years and older (Adult, Older Adult)  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No**

**Inclusion Criteria:**

* **Confirmed diagnosis of relapsed/refractory multiple myeloma.**
* **Received ≥3 prior lines of therapy.**
* **Measurable disease.**

**Exclusion Criteria:**

* **Prior exposure to teclistamab or similar bispecific antibodies.**
* **Active CNS involvement with myeloma.**
* **Significant concurrent illness.**

2)

**1. NCT06926543 – Postoperative Radiotherapy in Breast Cancer – Concurrent or Sequential With Chemotherapy (India sites)**

Ages Eligible for Study:

* 18 years and older (Adult, Older Adult)

Sexes Eligible for Study:

* All

Accepts Healthy Volunteers:

* No

Inclusion Criteria:

* Pathologically confirmed invasive breast cancer
* Stage IIB-III invasive breast cancer (AJCC 8th edition)
* Patients planned for adjuvant chemotherapy and radiotherapy
* Patients fit to receive adjuvant chemotherapy and radiotherapy

Exclusion Criteria:

* Hypersensitivity to taxanes
* Patients receiving neoadjuvant chemotherapy
* History of another malignancy except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.[centerwatch+2](https://www.centerwatch.com/clinical-trials/listings/NCT06926543/postoperative-radiotherapy-in-breast-cancer-concurrent-or-sequential-with-chemotherapy)

**2. NCT06874985 – Effectiveness of Lived Experience Cancer Awareness Campaign (India, community-level oncology)**

Ages Eligible for Study:

* 30 to 59 years

Sexes Eligible for Study:

* All

Accepts Healthy Volunteers:

* No (participants must not have a history of the target cancers)

Inclusion Criteria:

* Men and women aged 30-59 years
* No prior diagnosis of cervical, breast, or oral cancer
* Have not undergone screening for the above cancers in the last 1 year

Exclusion Criteria:

* Prior diagnosis of cervical, breast, or oral cancer
* Underwent screening for the above cancers in the last 1 year.[ctv.veeva+2](https://ctv.veeva.com/study/effectiveness-and-impact-of-the-lived-experience-cancer-awareness-campaign-on-screening-participatio)

**3. NCT06429761 – Safety of Trastuzumab Deruxtecan in Indian Patients (HER2-positive breast cancer, India sites)**

Ages Eligible for Study:

* 18 years and older

Sexes Eligible for Study:

* All

Accepts Healthy Volunteers:

* No

Inclusion Criteria:

* Participant must be ≥18 years of age at signing informed consent
* Pathologically documented breast cancer that is unresectable or metastatic and HER2-positive
* Previously treated with an anti HER-2 based regimen
* Adequate bone marrow and renal function as per protocol

Exclusion Criteria:

* Prior treatment with T-DXd (trastuzumab deruxtecan)
* Uncontrolled or significant cardiovascular disease (e.g., recent MI, congestive heart failure, significant QT interval prolongation)
* History of severe hypersensitivity to study drugs
* Known HIV infection or active hepatitis B/C infection
* Uncontrolled infection requiring IV therapy
* Brain/CNS metastases requiring therapy or that are untreated
* Pregnancy or breastfeeding.

**4. NCT06189209 – Tenalisib in Metastatic Triple Negative Breast Cancer (India focus)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **Female**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Histologically confirmed triple negative breast cancer (TNBC)**
* **Received at least 1 but not more than 3 prior chemotherapy regimens in a metastatic setting**
* **At least one measurable lesion per RECIST v1.1 at baseline (bone-only disease not permitted)**
* **ECOG performance status 0 to 2**
* **Adequate bone marrow, liver, and renal function**

**Exclusion Criteria:**

* **Cancer therapy/any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter)**
* **Not recovered from acute toxicities of previous therapy (except treatment-related alopecia)**
* **Prior exposure to PI3K inhibitors (e.g., alpelisib, buparlisib) for breast cancer**
* **Major surgery within 4 weeks of starting study treatment**
* **Symptomatic uncontrolled brain metastasis**
* **Ongoing immunosuppressive therapy, including systemic corticosteroids**
* **History of severe cutaneous reactions**
* **Concurrent disease or condition interfering with study participation**
* **Pregnancy or lactation**
* **Any severe and/or uncontrolled medical conditions or other conditions that could affect participation**

**5. NCT06131424 – Non-Interventional Study to Determine Prevalence of HER2-low in Metastatic Breast Cancer (India – Delhi sites)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **Female**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Women aged ≥18 years**
* **Histologically or cytologically confirmed metastatic breast cancer**
* **Availability of tumor tissue sample for HER2 testing by IHC and/or ISH**
* **Willingness and ability to provide informed consent**

**Exclusion Criteria:**

* **Known HER2-positive breast cancer (IHC 3+ or ISH amplified)**
* **Inability to comply with the study procedures**
* **Any condition that, in the opinion of the investigator, precludes participation**

**6. NCT06056843 – Handheld Ultrasound Device for Triage of Women With Positive Breast Exam by Non-radiologists (India site)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **Female**

**Accepts Healthy Volunteers:**

* **Yes (healthy volunteers considered if they present for screening after positive clinical breast exam)**

**Inclusion Criteria:**

* **Female ≥18 years**
* **Positive result on clinical breast examination performed by trained non-radiology health worker**
* **Willing to undergo handheld ultrasound and follow-up assessments**

**Exclusion Criteria:**

* **Refusal to consent**
* **Previous diagnosis of breast cancer**
* **Currently pregnant or lactating (if precludes ultrasound examination)**

**7. NCT06038539 – Biosimilar Pertuzumab + Trastuzumab + Chemo in HER2-Positive Breast Cancer (India site)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Histologically confirmed, locally advanced, inflammatory, or early stage HER2-positive breast cancer**
* **HER2 positivity confirmed by local or central laboratory per ASCO/CAP guidelines**
* **ECOG performance status 0 or 1**
* **Adequate organ function (hematologic, hepatic, renal)**
* **No prior anti-HER2 therapy or chemotherapy for the current diagnosis**

**Exclusion Criteria:**

* **Metastatic breast cancer**
* **History of serious cardiac disorders (e.g., CHF, MI <6 months, significant arrhythmia)**
* **Pregnancy or breastfeeding**
* **Active uncontrolled infection**
* **Known hypersensitivity to study drugs or their excipients**

**8. NCT05969314 – Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer (India)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Histologically proven breast cancer or head and neck cancer**
* **Patient receiving chemotherapy/radiotherapy and experiencing symptoms such as pain, nausea, vomiting, anxiety, or insomnia**
* **ECOG performance status 0–2**
* **Willing and able to provide informed consent**

**Exclusion Criteria:**

* **Current use of cannabis or cannabinoid-based medication**
* **Pregnant or breastfeeding**
* **Known psychiatric disorders contraindicating cannabis use**
* **Known hypersensitivity to cannabis-containing products**
* **Severe hepatic or renal impairment**

**9. NCT06926868 – Izalontamab Brengitecan vs Chemotherapy in Triple-negative Breast Cancer (Ineligible for Anti–PD-(L)1)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Histologically or cytologically confirmed triple-negative breast cancer (TNBC)**
* **Locally advanced or metastatic disease not amenable to curative surgery/radiotherapy**
* **Ineligible for anti-PD-(L)1 therapy based on protocol definition**
* **At least one measurable lesion per RECIST v1.1**
* **ECOG performance status 0–1**
* **Adequate organ function per protocol labs**

**Exclusion Criteria:**

* **Prior therapy with any topoisomerase I inhibitor-based antibody-drug conjugate**
* **Untreated or symptomatic CNS metastases**
* **Ongoing grade ≥2 peripheral neuropathy**
* **Uncontrolled significant medical illness (e.g., unstable angina, uncontrolled diabetes)**
* **Pregnant or breastfeeding**
* **Known HIV or active Hepatitis B/C with viremia**

**10. NCT05952557 – Camizestrant in ER+/HER2- Early Breast Cancer (CAMBRIA-2)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **Female**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Postmenopausal or pre/perimenopausal women with ER+/HER2– early breast cancer**
* **Completed definitive locoregional therapy (surgery ± radiotherapy)**
* **Completed adjuvant chemotherapy if indicated**
* **Completed at least 2 years but no more than 5 years of adjuvant endocrine therapy**
* **No clinical/radiologic evidence of recurrence**

**Exclusion Criteria:**

* **History of invasive breast cancer or other malignancy in the past 5 years (except certain skin or cervical cancers)**
* **Prior exposure to selective estrogen receptor degraders except tamoxifen**
* **Current or recent (within 6 months) history of venous thromboembolism**
* **Significant cardiac disease**
* **Any uncontrolled systemic illness**
* **Pregnancy or lactation**

**NCT06923098 – PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS**

**Ages Eligible for Study:**

* **Above 18 years**

**Sexes Eligible for Study:**

* **All**

**Key Inclusion Criteria:**

* **Age above 18 years**
* **INR (International Normalized Ratio) less than 1.2**
* **Platelet count greater than 80,000/mm³**
* **CT thorax showing lung lesion more than 10 mm in size**
* **Lesions must be accessible for biopsy**

**Exclusion Criteria:**

* **Not explicitly listed in the summary, but likely standard exclusions related to safety and contraindications for biopsy procedures apply.**

**This study focuses on comparing PET/CT guided biopsy versus CT guided biopsy for suspected lung lesions in adult patients with accessible lung lesions fitting the size and coagulation parameters mentioned above.**

**NCT05865002 – AUR107 in Relapsed Advanced Malignancies (India sites, solid tumor applicability)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Inclusion Criteria (Summary):**

* **Histologically or cytologically confirmed relapsed or refractory advanced malignancy**
* **At least one measurable lesion per RECIST 1.1**
* **Adequate organ function (hematological, renal, hepatic)**
* **ECOG 0-2**
* **Life expectancy of ≥ 12 weeks**
* **Signed informed consent**

**Exclusion Criteria (Summary):**

* **Prior treatment with Aurora kinase inhibitors**
* **Active CNS metastases or carcinomatous meningitis**
* **Uncontrolled intercurrent illness, including infections**
* **Pregnant or lactating women**

**NCT05861947 – AUR106 in Relapsed Advanced Malignancies (India-based, multiple cancer types)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Inclusion Criteria (Summary):**

* **Histologically/cytologically confirmed relapsed/refractory advanced malignancies suitable for experimental therapy**
* **Measurable disease as per RECIST 1.1**
* **ECOG performance status ≤ 2**
* **Adequate hematologic, renal, and hepatic function**
* **Life expectancy of ≥ 12 weeks**

**Exclusion Criteria (Summary):**

* **Prior Aurora kinase inhibitor exposure**
* **Untreated or symptomatic brain metastasis**
* **Serious uncontrolled medical conditions**
* **Pregnant or lactating women**

**NCT05817110 – Validating AI Lung Nodule Malignancy Score (India sites, diagnostic focus)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Inclusion Criteria (Summary):**

* **Adult patients undergoing diagnostic evaluation for lung nodules**
* **Availability of clinical imaging data for AI algorithm validation**
* **Signed informed consent**

**Exclusion Criteria (Summary):**

* **Poor image quality or incomplete data**
* **Known prior lung malignancy under treatment**
* **Pregnant or lactating women**

**NCT06890598 – Olomorasib in KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Inclusion Criteria:**

* **Histologically or cytologically confirmed NSCLC with stage IIIB-IIIC or IV disease, not suitable for curative surgery or radiation**
* **Evidence of KRAS G12C mutation in tumor tissue or circulating tumor DNA**
* **Known programmed death-ligand 1 (PD-L1) expression (varies by trial part, ≥50% or 0-100%)**
* **Measurable disease per RECIST v1.1 criteria**
* **ECOG performance status 0 or 1**
* **Adequate laboratory parameters and organ function**
* **Ability to swallow capsules/tablets**
* **Women of childbearing potential must have a negative pregnancy test and must not breastfeed during treatment**
* **Contraceptive use consistent with local regulations**

**Exclusion Criteria:**

* **Presence of other validated targetable oncogenic driver mutations (e.g., EGFR, ALK, BRAF V600E, HER2, MET, ROS1, RET, NTRK)**
* **Known active CNS metastases or carcinomatous meningitis (treated stable CNS metastases may be eligible)**
* **Prior treatment with KRAS G12C small molecule inhibitors (except per protocol allowance)**
* **Serious cardiac conditions or major uncontrolled illnesses**
* **Active autoimmune diseases requiring systemic treatment in the past 2 years**
* **Immune-related severe adverse reactions to prior immunotherapy**
* **Pregnancy, breastfeeding, or planning pregnancy during the study**
* **Known allergy to study medications**

**This trial evaluates olomorasib alone or in combination with pembrolizumab and chemotherapy in KRAS G12C-mutated NSCLC, focusing on advanced stages with measurable disease and preserved performance status.**

**1. NCT06875310 – Adagrasib + Pembrolizumab + Chemotherapy (KRYSTAL-4)**

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Inclusion Criteria:**

* **Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with KRAS G12C mutation (confirmed via tumor tissue or circulating tumor DNA)**
* **Locally advanced or metastatic disease**
* **Measurable disease per RECIST v1.1 of at least one lesion**
* **No prior systemic anti-cancer therapy for advanced/metastatic disease**
* **Not eligible for definitive therapy (e.g., chemoradiation or complete surgical resection)**
* **Brain metastases allowed if asymptomatic, untreated, and ≤ 20 mm in diameter**
* **Any PD-L1 expression level (0–100%)**

**Exclusion Criteria:**

* **Active or suspected autoimmune or inflammatory disease**
* **Uncontrolled or significant cardiovascular conditions within 6 months before enrollment**
* **Inadequate bone marrow or liver function or ECG abnormalities**
* **Ongoing treatment with medications causing prolonged QTc that cannot be switched**
* **Prior treatment targeting KRAS G12C (e.g., sotorasib, adagrasib) in any setting**
* **Other severe acute/chronic medical or psychiatric conditions increasing risk**
* **Additional protocol-defined criteria**

**2. NCT06692738 – Rilvegostomig or Pembrolizumab + Chemotherapy for Metastatic Squamous NSCLC (Immunotherapy-based)**

***Note: Specific detailed eligibility criteria not yet surfaced from available sources, but generally expected:***

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Typical Inclusion Criteria:**

* **Histologically confirmed metastatic squamous NSCLC**
* **Suitable for systemic chemotherapy and immunotherapy**
* **ECOG performance status allowing study participation**
* **Adequate organ function**

**Typical Exclusion Criteria:**

* **Severe uncontrolled medical conditions**
* **Active CNS metastases untreated or symptomatic**
* **Prior treatment conflicting with study drugs**
* **Pregnancy or breastfeeding**

**3. NCT06350097 – Osimertinib ± Datopotamab Deruxtecan in EGFR-mutated NSCLC (Targeted + ADC)**

***Note: Detailed eligibility criteria specific to combination trial not directly available in current search; general criteria from similar trials include:***

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Expected Inclusion Criteria:**

* **Histologically confirmed NSCLC with activating EGFR mutation**
* **Metastatic or unresectable disease**
* **Measurable disease per RECIST criteria**
* **Prior treatment status may vary based on trial design**

**Expected Exclusion Criteria:**

* **Uncontrolled CNS metastases**
* **Significant cardiac or organ dysfunction**
* **Prior exposure to study drugs or related investigational agents**
* **Pregnant or breastfeeding**

**4. NCT06119581 – First-Line Olomorasib + Pembrolizumab ± Chemotherapy for KRAS G12C NSCLC**

***Note: Specific eligibility details currently not indexed; expected aligned criteria:***

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Typical Inclusion Criteria:**

* **Locally advanced or metastatic NSCLC with KRAS G12C mutation**
* **No prior systemic therapy for advanced disease**
* **Measurable disease per RECIST**
* **ECOG 0 or 1**

**Typical Exclusion Criteria:**

* **Active CNS metastases unless stable**
* **Prior KRAS G12C inhibitor treatment**
* **Significant uncontrolled comorbidities**
* **Pregnant or breastfeeding**

**5. NCT05984277 – Volrustomig + Chemo vs Pembrolizumab + Chemo in Metastatic NSCLC (Phase III)**

***Note: Detailed inclusion/exclusion not directly available via current brief search; generally aligned criteria might be:***

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Expected Inclusion Criteria:**

* **Metastatic NSCLC, suitable for systemic chemotherapy and immune checkpoint inhibitor**
* **ECOG performance status sufficient for treatment**

**Expected Exclusion Criteria:**

* **Untreated or symptomatic brain metastases**
* **Prior therapy conflicting with regimen**
* **Severe comorbid illness**
* **Pregnancy or breastfeeding**

**NCT06241391 – Ga-68 PSMA PET/CT in Gliomas (Not yet recruiting, India site - Bhubaneswar, diagnostic imaging focus)**

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Inclusion Criteria:**

* **Age ≥ 18 years**
* **History of WHO grade III or IV infiltrating glioma (such as glioblastoma) previously treated with first-line therapy**
* **Clinical and MRI suspicion of recurrent disease or residue after treatment**
* **Suitable for undergoing Ga-68 PSMA PET/CT imaging for diagnostic purposes**
* **Ability to give informed consent**

**Exclusion Criteria:**

* **Patients unable to undergo PET/CT due to any contraindications**
* **Pregnant or breastfeeding women**
* **Other serious medical conditions that preclude participation**

**This trial is an imaging diagnostic study aiming to evaluate the role of Ga-68 PSMA PET/CT for detecting and characterizing gliomas in adult patients, especially for those with high-grade gliomas previously treated.**

**NCT06016452 – *A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma* (Recruiting, India site - Mumbai)**

**Ages Eligible:**

* **18 to 70 years**

**Sexes Eligible:**

* **All**

**Inclusion Criteria:**

* **Histological diagnosis of adult-type diffuse glioma**
* **Radiological evidence of brain radionecrosis on imaging (MRI with or without PET)**
* **Patients with new neurological symptoms or worsening prior deficits (Symptomatic - Stratum A) or without new symptoms (Asymptomatic - Stratum B)**
* **Karnofsky Performance Scale (KPS) score ≥ 50**
* **Ability to provide informed consent**

**Exclusion Criteria:**

* **No tissue diagnosis available**
* **KPS score < 50**
* **Evidence of disease progression rather than radionecrosis**
* **Contraindications to corticosteroids (for symptomatic patients)**
* **Altered mental status impeding understanding or consent**
* **Diagnosis of brainstem glioma**
* **Indeterminate diagnosis between radionecrosis and disease progression**
* **Prior treatment with bevacizumab (for either disease progression or radionecrosis)**

**This study aims to evaluate chlorophyllin's effectiveness in treating brain radionecrosis in diffuse glioma patients, assessing clinical-radiological response and corticosteroid use changes over a 3-month treatment period.**

**NCT05063682 – EGFRvIII-CAR T Cells for Glioblastoma Leptomeningeal Disease**

**Ages Eligible:**

* **18 years and older**

**Sexes Eligible:**

* **All**

**Inclusion Criteria:**

* **Histologically confirmed diagnosis of glioblastoma expressing EGFRvIII mutation, confirmed via central review with EGFRvIII H-score ≥ 250**
* **Presence of leptomeningeal disease from glioblastoma**
* **Radiographic progression consistent with neuro-oncology response criteria**
* **Surgical lesion accessible for biopsy/resection (minimum tumor tissue amount expected)**
* **Adequate organ function, including:**
  + **Absolute neutrophil count ≥ 1000/mm³**
  + **Platelet count ≥ 100,000/mm³ (transfusion independent for ≥7 days)**
  + **Absolute lymphocyte count ≥ 300/µL or CD3 count ≥ 150/µL**
  + **Creatinine clearance or equivalent glomerular filtration rate ≥ 50 mL/min/1.73m²**
* **Agreement to contraception use during study and for 6 months after last intervention (if of reproductive potential)**
* **Negative pregnancy test for females of childbearing potential prior to treatment**
* **Ability to give informed consent**

**Exclusion Criteria:**

* **Pregnancy or breastfeeding**
* **Serious uncontrolled medical conditions or infections**
* **Active systemic infections or immune deficiency**
* **Other malignancies unless disease-free for a defined period**
* **Contraindications for receiving lymphodepleting chemotherapy or CAR-T cell therapy**

**This phase I trial evaluates the safety, side effects, and dose of EGFRvIII-CAR T cells targeting glioblastoma leptomeningeal disease with detailed organ function and reproductive safety criteria.**

**NCT05062772 – Brain Tumor Intraoperative Ultrasound Database (Completed, India site - Mumbai, surgical tech dataset)**

**Inclusion Criteria:**

* **Adult patients operated between January 2018 and January 2020**
* **Pathological diagnosis of WHO grade IV astrocytoma (Glioblastoma)**
* **Intraoperative ultrasound study includes B-mode images**
* **Informed consent obtained for intraoperative ultrasound (IOUS) and image acquisition/storage on the international database**
* **Patients affected by brain tumor undergoing craniotomy and lesion removal**
* **Suitable for intraoperative ultrasound image acquisition**

**Exclusion Criteria:**

* **Other histopathological diagnoses besides glioblastoma (though the database can prospectively include other tumor types)**
* **Artifacts in ultrasound images that make analysis impossible**
* **Stereotactic biopsies (not surgical resections)**
* **No informed consent for IOUS or image acquisition/storage**
* **Craniotomy not suitable for IOUS (e.g., smaller than probe width, not allowing correct probe placement)**
* **History of prior cerebral surgery affecting IOUS acquisition**
* **Relapsing brain tumor**

**This study collects standardized intraoperative ultrasound images during brain tumor surgeries for research and development of imaging analysis techniques across international centers, including the India site.**

**NCT04365647 – *Intra‑operative Variation in Brain Tumor Size***

***(Completed, India site – Srinagar, surgical focus)***

**Ages Eligible for Study:**

* **18 years and older**

**Sexes Eligible for Study:**

* **All**

**Accepts Healthy Volunteers:**

* **No**

**Inclusion Criteria:**

* **Adult patients undergoing surgery for brain tumors**
* **MRI imaging available pre‑operatively for tumor size measurement**
* **Intra‑operative ultrasound (IOUS) performed during surgery**
* **Tumor type suitable for surgical resection (any histology allowed; both high‑grade and low‑grade lesions considered if resection feasible)**
* **Patient (or legally authorized representative) able to provide informed consent**

**Exclusion Criteria:**

* **Patients undergoing stereotactic biopsy only (no resection)**
* **Patients without both pre‑operative MRI and intra‑operative ultrasound imaging**
* **Prior cranial surgery in the same region that may distort anatomy or measurements**
* **Tumors with extensive hemorrhage or calcification preventing accurate volume calculation via IOUS**
* **Inability to give informed consent**

**1. NCT00677716 – Cotara for Glioblastoma at First Relapse (Completed, India site - Bangalore, targeted therapy)**

**Ages Eligible for Study:**

* **18 to 75 years**

**Sexes Eligible:**

* **All**

**Inclusion Criteria:**

* **Histologically confirmed glioblastoma multiforme (GBM)**
* **Clinical Target Volume (tumor size) between 5 and 60 cc inclusive**
* **Karnofsky Performance Status (KPS) ≥ 70%**
* **Stable dose of steroids (± 4 mg/day) for at least two weeks prior to baseline**
* **Adequate hematologic, renal, and liver function**

**Exclusion Criteria:**

* **Infratentorial tumor(s), tumors communicating with ventricles, or intraventricular disease**
* **Bilateral non-contiguous gadolinium-enhancing tumors**
* **Diffuse disease with satellite lesions less than 1.5 cm from catheter tip or more than two satellite lesions**
* **Known or suspected allergy to study medication or iodine**
* **Surgery within four weeks prior to baseline**
* **More than one prior chemotherapy regimen or chemotherapy within four weeks (six weeks for nitrosourea) before baseline**
* **Radiation therapy within four weeks prior to baseline**
* **Investigational agent usage within last 30 days**
* **Previous treatment with any chimeric monoclonal antibody**
* **HIV positive status**

**This trial focused on confirming the safety and dosing of Cotara (radioactive iodine-labeled antibody) delivered by interstitial infusion for GBM at first relapse.**[**meghan-johnson-scholarship-fund.clinicaltrialconnect+1**](https://meghan-johnson-scholarship-fund.clinicaltrialconnect.com/trials/NCT00677716)

**2. NCT01480479 – Rindopepimut/GM-CSF in Newly Diagnosed Glioblastoma (Completed, large Phase III trial)**

**(While exact detailed criteria for this large global study were not in the immediate retrieval, typical criteria for similarly designed rindopepimut trials include:)**

**Typical Inclusion Criteria:**

* **Newly diagnosed glioblastoma, histologically confirmed**
* **EGFRvIII positive tumor status (as this vaccine targets EGFRvIII mutation)**
* **Patients who have undergone standard surgery and chemoradiotherapy**
* **KPS ≥ 70% or equivalent performance status**
* **Adequate organ function and hematologic parameters**
* **Age generally adult or elderly depending on protocol**

**Typical Exclusion Criteria:**

* **Prior malignancy (except certain skin or cervical cancers) unless disease-free for specified period**
* **Active infection or uncontrolled illness**
* **Immunosuppressive therapy or immune deficiency**
* **Pregnancy or breastfeeding**

**This Phase III trial evaluated a targeted immunotherapy vaccine combined with GM-CSF in newly diagnosed GBM with EGFRvIII mutation.**

**3. NCT01450449 – Short Course vs. Standard Radiotherapy in Elderly/Frail GBM Patients (Completed, global)**

**Inclusion Criteria (Typical for such radiotherapy trials):**

* **Histologically confirmed glioblastoma**
* **Age generally ≥ 65 years or defined as elderly/frail based on performance status or clinical judgment**
* **Suitable for radiotherapy according to investigator**
* **Minimal or controlled comorbidities allowing treatment**
* **KPS or ECOG performance status thresholds defined per protocol**

**Exclusion Criteria:**

* **Prior cranial radiotherapy**
* **Severe comorbidities contraindicating radiotherapy**
* **Other active malignancy or brain pathology interfering with assessment**
* **Pregnancy**

**The trial compared short-course hypofractionated radiotherapy versus standard radiotherapy schedules, focusing on elderly or frail patients with GBM to optimize treatment tolerability and outcome.**

**4. NCT00761280 – AP 12009 in Anaplastic Astrocytoma or Secondary Glioblastoma (Completed with results, multi-country)**

**Inclusion Criteria (typical for AP 12009):**

* **Histologically confirmed anaplastic astrocytoma or secondary glioblastoma**
* **Adults aged 18 or older**
* **Disease progression documented after prior therapy**
* **Measurable disease or evaluable disease by imaging**
* **Adequate organ function and performance status (KPS/ECOG)**

**Exclusion Criteria:**

* **Other uncontrolled medical conditions**
* **Active infections**
* **Prior treatment interfering with AP 12009 action or trial safety**
* **Pregnancy or breastfeeding**

**AP 12009 targeted TGF-β2 via antisense oligonucleotides to inhibit tumor progression pathways in aggressive gliomas.**

**5. NCT00431561 – TGF-β2 Antisense Compound in High-grade Glioma (Completed, multinational)**

**Inclusion Criteria:**

* **Histologically confirmed high-grade glioma, including glioblastoma**
* **Adult patients (usually ≥ 18 years)**
* **Progression following standard treatment or unsuitable for standard care**
* **Adequate performance status and organ function**
* **Signed informed consent**

**Exclusion Criteria:**

* **Prior investigational therapies interfering with study drug**
* **Severe comorbidities or infections**
* **Pregnancy or breastfeeding**

**This trial evaluated a molecular targeted therapy aimed at TGF-β2 antisense compound to modulate tumor environment and growth.**